Immuno-Biological Laboratories Co., Ltd. Financial Summary for the 2nd Quarter (Interim) [Japanese GAAP] (Consolidated) November 11, 2026

Overview of Results

Immuno-Biological Laboratories Co., Ltd. recorded a significant increase in net sales in the 2nd quarter (interim) of the fiscal year ending March 2027, primarily driven by antibody-related businesses. Expansion of overseas sales, yen depreciation, and increased revenues from contract services and in-house in vitro diagnostic products contributed to the growth, resulting in total net sales of 563,168 thousand yen and operating income of 197,477 thousand yen, a substantial improvement year-over-year. Although sales in the cosmetics-related business declined, consolidated ordinary income was 206,867 thousand yen and net income attributable to owners of parent for the interim was 186,570 thousand yen, demonstrating steady growth. The financial position remains solid with an equity ratio of 86.4% and cash and cash equivalents of 822,660 thousand yen.

Outlook and Considerations

Full-year forecasts are net sales 1,087,000 thousand yen, operating income 322,000 thousand yen, ordinary income 322,000 thousand yen, and net income attributable to owners of parent 347,000 thousand yen (earnings per share 37.26 yen). The interim results are progressing within the assumptions. Exchange rate movements and trends in contract services and overseas markets may impact performance, while growth in antibody-related businesses is expected to continue contributing to profits.